US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
29/12/20 - 18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products
Molecular
07/12/20 - 10:35
Communication on total amount of voting rights (563.18 KB)
Other
04/12/20 - 16:14
Form 3F (November 2020) (10.2 KB)
Other
01/12/20 - 6:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products
Immunodiagnostic
11/11/20 - 12:41
North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data
26/10/20 - 18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products
Immunodiagnostic
23/10/20 - 19:41
Conclusion treasury shares buy-back plan (314.28 KB)
Other
23/10/20 - 19:37
Weekly report treasury shares buy-back (436.92 KB)
Other
16/10/20 - 18:28
Weekly report treasury shares buy-back (425.19 KB)
Other
01/10/20 - 7:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products
Immunodiagnostic
01/10/20 - 7:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products
Immunodiagnostic
23/09/20 - 7:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
Acquisition / Partnership
16/09/20 - 14:30
Update Annual Calendar of Corporate Events 2020 (222.26 KB)
Other
16/09/20 - 7:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products
Molecular
08/09/20 - 7:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
Acquisition / Partnership
07/09/20 - 18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products
Molecular
06/08/20 - 7:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products
Immunodiagnostic
31/07/20 - 16:04
Weekly report treasury shares buy-back (380.16 KB)
Other
30/07/20 - 13:16
North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data
24/07/20 - 17:19
Weekly report treasury shares buy-back (363.73 KB)
Other
17/07/20 - 18:19
Weekly report treasury shares buy-back (360.09 KB)
Other
10/07/20 - 18:23
Weekly report treasury shares buy-back (374 KB)
Other
09/07/20 - 7:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products
Immunodiagnostic
07/07/20 - 7:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products
Molecular
30/06/20 - 7:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products
Immunodiagnostic
19/06/20 - 17:20
Weekly report treasury shares buy-back (399.38 KB)
Other
17/06/20 - 16:09
Start up of the treasury shares buy-back plan (481.28 KB)
Other
12/06/20 - 7:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products
Molecular
10/06/20 - 15:40
Shareholders' Meeting June 10, 2020 (308.25 KB)
Other
03/06/20 - 14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products
Immunodiagnostic
02/06/20 - 14:58
Communication total amount voting rights (record date) (267.83 KB)
18/05/20 - 11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products
Immunodiagnostic
13/05/20 - 13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data
25/04/20 - 16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products
Immunodiagnostic
17/04/20 - 18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products
Immunodiagnostic
07/04/20 - 7:14
IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products
Immunodiagnostic
26/03/20 - 18:14
Update Annual Calendar of Corporate Events 2020 (277.25 KB)
Other
21/03/20 - 20:29
Shareholders' Meeting date change (288.23 KB)
Other
20/03/20 - 7:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products
Molecular
13/03/20 - 17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products
Molecular
11/03/20 - 13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data
10/03/20 - 8:20
DiaSorin - Development of Coronavirus test (404.03 KB)
Products
Molecular
02/03/20 - 8:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
Acquisition / Partnership
07/02/20 - 8:06
Communication on total amount of voting rights (281.13 KB)
Other
15/01/20 - 16:51
Annual Calendar of Corporate Events 2020 (124.73 KB)
Other